|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
MX2016000364A
(es)
|
2013-07-12 |
2016-05-09 |
Ophthotech Corp |
Metodos para tratar o prevenir afecciones oftalmologicas.
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
RU2723940C2
(ru)
*
|
2014-03-21 |
2020-06-18 |
Экс-Боди, Инк. |
Биспецифические антигенсвязывающие полипептиды
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
SG11201703428SA
(en)
|
2014-11-10 |
2017-05-30 |
Hoffmann La Roche |
Bispecific antibodies and methods of use in ophthalmology
|
|
AU2015345322A1
(en)
|
2014-11-10 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-PDGF-B antibodies and methods of use
|
|
WO2016075034A1
(en)
|
2014-11-10 |
2016-05-19 |
F. Hoffmann-La Roche Ag |
ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
|
|
CA2963606A1
(en)
|
2014-11-10 |
2016-05-19 |
F.Hoffmann-La Roche Ag |
Anti-ang2 antibodies and methods of use
|
|
US20160144025A1
(en)
*
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
|
JP2018506280A
(ja)
*
|
2015-02-06 |
2018-03-08 |
カドモン コーポレイション，リミティド ライアビリティ カンパニー |
免疫調節薬
|
|
JP6836512B2
(ja)
|
2015-03-31 |
2021-03-03 |
イルドン ファーム カンパニー リミテッド |
組織透過性ペプチドと抗血管内皮細胞成長因子製剤が融合された融合タンパク質を有効成分として含む眼疾患の予防及び治療用薬学的組成物
|
|
CN107849126B
(zh)
|
2015-07-29 |
2022-04-08 |
阿勒根公司 |
仅有重链的抗ang-2抗体
|
|
TW202440903A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（一）
|
|
PL3389636T3
(pl)
|
2015-12-16 |
2022-11-28 |
Regeneron Pharmaceuticals, Inc. |
Kompozycje i metody wytwarzania mikrocząstek białkowych
|
|
WO2017117464A1
(en)
|
2015-12-30 |
2017-07-06 |
Kodiak Sciences Inc. |
Antibodies and conjugates thereof
|
|
BR112018076260A2
(pt)
|
2016-06-20 |
2019-03-26 |
Kymab Limited |
anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
|
|
CA3029332A1
(en)
*
|
2016-07-01 |
2018-01-04 |
Ludwig Institute For Cancer Research Ltd |
Methods and compositions for pdgf-cc inhibition
|
|
KR102369014B1
(ko)
|
2016-08-16 |
2022-03-02 |
리제너론 파아마슈티컬스, 인크. |
혼합물로부터 개별 항체들을 정량하는 방법
|
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
CN109021104B
(zh)
*
|
2017-06-12 |
2022-08-12 |
上海睿智化学研究有限公司 |
一种抗人血小板衍生生长因子β受体的抗体及其应用
|
|
MX2020000228A
(es)
|
2017-07-06 |
2020-08-10 |
Regeneron Pharma |
Proceso de cultivo celular para producir una glicoproteina.
|
|
JP7321159B2
(ja)
|
2017-12-22 |
2023-08-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
薬剤生成物不純物を特性決定するためのシステム及び方法
|
|
BR112020013336A2
(pt)
|
2018-01-31 |
2020-12-01 |
Regeneron Pharmaceuticals, Inc. |
produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário.
|
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
MX2020008988A
(es)
|
2018-02-28 |
2020-09-28 |
Regeneron Pharma |
Sistemas y metodos para la identificacion de contaminantes virales.
|
|
BR112020017872A2
(pt)
|
2018-03-02 |
2020-12-22 |
Kodiak Sciences Inc. |
Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
DK3768709T3
(da)
|
2018-03-19 |
2024-01-29 |
Regeneron Pharma |
Mikrochip-kapillærelektroforese-assays og reagenser
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
GB201806918D0
(en)
*
|
2018-04-27 |
2018-06-13 |
Enleofen Bio Pte Ltd |
Combination treatment for eye fibrosis
|
|
CN108586611B
(zh)
*
|
2018-04-28 |
2021-01-26 |
暨南大学 |
重组全人源抗破伤风毒素单克隆抗体
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
IL280880B2
(en)
|
2018-08-27 |
2025-04-01 |
Regeneron Pharma |
Using Raman Spectroscopy in Downstream Purification
|
|
BR112020026348A2
(pt)
|
2018-08-30 |
2021-03-30 |
Regeneron Pharmaceuticals, Inc. |
Método para avaliar a estequiometria e distribuição de tamanho de complexos de proteínas, para selecionar um medicamento de proteína principal e para caracterizar complexos de proteínas, e, composição farmacêutica
|
|
BR112021006352A2
(pt)
|
2018-10-05 |
2021-07-06 |
Univ Ewha Ind Collaboration |
anticorpo receptor de pdgf e uso do mesmo
|
|
FI3857237T3
(fi)
|
2019-01-16 |
2023-05-03 |
Regeneron Pharma |
Disulfidisidosten luonnehtimismenetelmiä
|
|
EP3935084B1
(en)
*
|
2019-03-08 |
2024-06-12 |
LinXis B.V. |
Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
|
|
CN114364693A
(zh)
|
2019-05-03 |
2022-04-15 |
新加坡保健服务私人有限公司 |
代谢性疾病的治疗和预防
|
|
US20200363400A1
(en)
|
2019-05-13 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Competitive Ligand Binding Assays
|
|
CN120334439A
(zh)
|
2019-09-24 |
2025-07-18 |
里珍纳龙药品有限公司 |
用于色谱介质的使用和再生的系统及方法
|
|
WO2021072265A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
CN119318636A
(zh)
|
2019-11-25 |
2025-01-17 |
里珍纳龙药品有限公司 |
使用非水性乳液的持续释放调配物
|
|
WO2021142086A1
(en)
|
2020-01-08 |
2021-07-15 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
|
EP4354145B1
(en)
|
2020-01-21 |
2025-09-17 |
Regeneron Pharmaceuticals, Inc. |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
|
WO2021158110A1
(en)
*
|
2020-02-07 |
2021-08-12 |
Biorion Technologies B.V. |
Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof
|
|
BR112023003273A2
(pt)
|
2020-08-31 |
2023-05-02 |
Regeneron Pharma |
Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina
|
|
US20240325562A1
(en)
*
|
2020-09-16 |
2024-10-03 |
Linxis B.V. |
Internalizing binding molecules
|
|
CA3191141A1
(en)
|
2020-11-25 |
2022-06-02 |
Hunter Chen |
Sustained release formulations using non-aqueous membrane emulsification
|
|
WO2022133135A1
(en)
|
2020-12-17 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
|
TW202233827A
(zh)
|
2021-01-20 |
2022-09-01 |
美商再生元醫藥公司 |
改良細胞培養中蛋白質效價的方法
|
|
AR125585A1
(es)
|
2021-03-03 |
2023-08-02 |
Regeneron Pharma |
Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
|
|
IL305731A
(en)
|
2021-03-26 |
2023-11-01 |
Regeneron Pharma |
Methods and systems for developing mixing protocols
|
|
BR112023024984A2
(pt)
|
2021-06-01 |
2024-02-20 |
Regeneron Pharma |
Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
|
|
TW202326138A
(zh)
|
2021-09-08 |
2023-07-01 |
美商再生元醫藥公司 |
用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
|
|
CN118139881A
(zh)
|
2021-09-20 |
2024-06-04 |
瑞泽恩制药公司 |
控制抗体异质性的方法
|
|
JP2024540835A
(ja)
|
2021-10-07 |
2024-11-06 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ｐＨメーター較正及び補正
|
|
IL311245A
(en)
|
2021-10-07 |
2024-05-01 |
Regeneron Pharma |
Systems and methods for pH modeling and control
|
|
CN118176167A
(zh)
|
2021-10-26 |
2024-06-11 |
瑞泽恩制药公司 |
用于产生实验室用水和分配处于不同温度的实验室用水的系统和方法
|
|
CN119137473A
(zh)
|
2022-03-18 |
2024-12-13 |
里珍纳龙药品有限公司 |
分析多肽变体的方法及系统
|
|
US11723955B1
(en)
|
2022-05-13 |
2023-08-15 |
Allgenesis Biotherapeutics Inc. |
VEGFR fusion protein pharmaceutical composition
|
|
EP4634659A1
(en)
|
2022-12-16 |
2025-10-22 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
EP4655595A1
(en)
|
2023-01-25 |
2025-12-03 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
WO2024158880A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
TW202445138A
(zh)
|
2023-02-01 |
2024-11-16 |
美商再生元醫藥公司 |
用於生物巨分子分析之具質譜法的不對稱流場流分離
|
|
WO2024178213A2
(en)
|
2023-02-22 |
2024-08-29 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
|
WO2024229136A1
(en)
|
2023-05-01 |
2024-11-07 |
Regeneron Pharmaceuticals, Inc. |
Multidose antibody drug products using phenol or benzyl alcohol
|
|
TW202528736A
(zh)
|
2023-09-08 |
2025-07-16 |
美商再生元醫藥公司 |
用於評估層析管柱完整性的方法及系統
|
|
US20250095773A1
(en)
|
2023-09-18 |
2025-03-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
US20250109905A1
(en)
|
2023-09-29 |
2025-04-03 |
Regeneron Pharmaceuticals, Inc. |
Lyophilization using controlled nucleation
|
|
WO2025085594A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
WO2025096932A1
(en)
|
2023-11-02 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
CN118440214B
(zh)
*
|
2024-04-02 |
2025-01-28 |
山东大学 |
一种靶向PDGFRβ的嵌合抗原受体、CAR-T细胞及应用
|